Clinical Significance and Expression of P16 in Chronic Myelogenous Leukemia

Objective To examine the expression levels of P16 in the patients with chronic myelogenous leukemia(CML),and evaluate the pathogenesis and clinical significance of P16 in CML.Methods The real-time quantitative polymerase chain reaction(RQ-PCR) was performed to detect the expression levels of P16 in the bone marrow samples of 18 patients with CML,and 16 samples of benign hemopoietic patients. The relationship between the expression levels of P16 and the progression and prognosis of patients with CML were analyzed.Results The level of P16 was apparently lower expressed in 18 patients with CML than the control group,there was significant difference between patiens with CML and control group(P0.05).The levels of P16 was apparently lower expressed in accelerated phase /blast crisis phase than in chronic phase and control group(P0.05). The levels of P16 was lower expressed in chronic phase than the control group(P0.05).Conclusion P16 has low expression in CML,the roles of P16 in CML may be an anti-oncogene,and the expression level is correlated with the progression and prognosis of patients with CML.